No Data
No Data
Express News | Citigroup Maintains Buy on Longboard Pharmaceuticals, Raises Price Target to $45
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Longboard Pharmaceuticals (LBPH Quick QuoteLBPH - Free Report) gained 14.4% on Jul 1 after it announced that the FDA has granted Breakthrough Therapy designation for its investigational drug, bexicaserin, to treat seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients aged two years or older.
Citi Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Raises Target Price to $45
Citi analyst David Hoang maintains $Longboard Pharmaceuticals(LBPH.US)$ with a buy rating, and adjusts the target price from $40 to $45.According to TipRanks data, the analyst has a success rate of 59
Optimistic Buy Rating for Longboard Pharmaceuticals Amid Breakthrough Therapy Designation and Strong Market Potential
Express News | Longboard Pharmaceuticals Inc : Citigroup Raises Target Price to $45 From $40
Evercore ISI Raises Price Target on Longboard Pharmaceuticals to $80 From $57, Keeps Outperform Rating
Longboard Pharmaceuticals (LBPH) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $32 to $90. Price: 30.95, Change: +0.03, Percent Change: +
No Data